NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 4 3

+8 more TTM periods

ROE
(43.22%) (49.96%) (38.89%) (50.60%)
ROA
(14.56%) (16.99%) (13.32%) (13.75%)
ROIC
(115.56%) (92.52%) (123.24%) 0.00%
Return on Tangible Assets
(28.58%) (33.69%) (26.04%) (33.88%)
Average Days of Receivables
76.12 79.24 82.49 70.88
Free Cash Flow per Share
(0.22) (0.42) (0.68) (0.58)
Free Cash Flow
(25.43) (48.07) (75.68) (65.17)
Capital Expenditures
(22.62) (21.19) (26.65) (30.69)
Other line items
Cash ROIC
(2.58%) (4.77%) (7.62%) (4.15%)
Accounts Receivable Turnover
5.09 5.09 5.09 5.91
Accounts Payable Turnover
1.42 1.50 1.47 1.50
Inventory Turnover
4.05 4.03 4.38 4.05
Average Days of Payables
285.86 277.62 267.35 274.40
Days of Inventory on Hand
92.33 94.82 89.92 90.23
Tax Rate
(0.03) (0.01) 0.00 0.18
Research and Development Expense of Revenue
32.14% 33.97% 34.26% 33.45%
Selling, General and Administrative Expense of Revenue
66.07% 68.41% 63.74% 69.43%
Share Based Compensation of Revenue
18.47% 20.51% 16.00% 23.01%
Interest Coverage
90.29 22.52 8.76 6.74
Operating CF/Net income
0.02 0.16 0.36 0.19
Depreciation/Fixed assets
0.01 (0.04) (0.09) (0.13)
Capex/Depreciation
(23.71) 5.61 3.09 2.43
Revenue per Share
6.03 5.91 5.88 5.74
Operating CF per Share
(0.02) (0.24) (0.44) (0.31)
Capex per Share
(0.19) (0.19) (0.24) (0.27)
Capex to Sales
0.03 0.03 0.04 0.05

Fold the line items

Columns are period end dates